As of the latest Form 4 filed May 27, 2026.
What Envista Holdings Corp insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 28 most recent filings for NVST.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | 2026-05-25 | Keel Paul A Chief Executive Officer | FTax | −12.8K | $23.43 | $300K | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-19 | Pierce James Andrew Director | AAward | +9.33K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-19 | Carruthers Wendy Director | AAward | +9.33K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-19 | Jain Vivek Director | AAward | +9.33K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-19 | Huennekens R Scott Director | AAward | +12.6K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-19 | GALLAHUE KIERAN Director | AAward | +9.33K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-19 | Raskas Daniel Director | AAward | +9.33K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-21 | 2026-05-19 | TSINGOS CHRISTINE A Director | AAward | +9.33K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Acurio Veronica President, Orthodontics | AAward | +7.61K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Acurio Veronica, President, Orthodontics | FTax | −1.41K | $29.59 | $41.8K | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Nilsson Stefan President, Nobel Biocare | AAward | +7.61K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Nilsson Stefan, President, Nobel Biocare | FTax | −182.00 | $29.59 | $5.39K | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Befidi Robert President, Diagnostics | AAward | +7.61K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Befidi Robert, President, Diagnostics | FTax | −2.18K | $29.59 | $64.4K | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Kaabi Faez C Chief Accounting Officer | AAward | +13.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Kaabi Faez C, Chief Accounting Officer | FTax | −4.96K | $29.59 | $147K | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Reis Mischa SVP, Strategy & Bus. Dev. | AAward | +5.92K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Reis Mischa, SVP, Strategy & Bus. Dev. | FTax | −2.98K | $29.59 | $88.1K | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Nance Mark E General Counsel | AAward | +12.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Nance Mark E, General Counsel | FTax | −3.37K | $29.59 | $99.7K | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Keel Paul A Chief Executive Officer | AAward | +48.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Keel Paul A, Chief Executive Officer | FTax | −11.8K | $29.59 | $350K | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Hammes Eric D. Chief Financial Officer | AAward | +16.1K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Hammes Eric D., Chief Financial Officer | FTax | −2.04K | $29.59 | $60.5K | No | Form 4 ↗ |
| 2026-02-11 | 2026-02-10 | Reis Mischa SVP, Strategy & Bus. Dev. | SSale | −5.63K | $30.00 | $169K | Yes (planned) | Form 4 ↗ |
| 2026-02-11 | 2026-02-10 | Reis Mischa, SVP, Strategy & Bus. Dev. | MExercise | +5.63K | $15.97 | $90.0K | Yes (planned) | Form 4 ↗ |
| 2026-02-11 | 2026-02-10 | Reis Mischa, SVP, Strategy & Bus. Dev. | SSale | −4.04K | $30.00 | $121K | Yes (planned) | Form 4 ↗ |
| 2026-02-11 | 2026-02-10 | Reis Mischa, SVP, Strategy & Bus. Dev. | MExercise | +4.04K | $19.04 | $76.9K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also NVST’s full analysis or the market-wide insider trading feed. The tabs above jump to NVST’s other SEC data.
Source: SEC Form 4 filings for NVST, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.